Brief: Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression After Single Ivt Injection Of Advm-022

Adverum Biotechnologies

09/06/2022 13:15

June 9 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES PRESENTS THREE-YEAR AFLIBERCEPT
PROTEIN
EXPRESSION AND IMPROVEMENT IN ANATOMIC OUTCOMES AFTER A SINGLE
IVT INJECTION OF ADVM-022 IN THE OPTIC STUDY IN WET AMD
    * ADVERUM - 3-YEAR AFLIBERCEPT PROTEIN EXPRESSION SHOWS
CONTINUOUS, CONSISTENT THERAPEUTIC LEVELS FROM ADVM-022 IN OPTIC
STUDY SUBJECTS WITH WET AMD

Source text for Eikon:  ID:nGNX12b369 
Further company coverage:  ADVM.O 

 ((reuters.briefs@thomsonreuters.com;))